NovaBay Pharmaceuticals (NBY) stock price, revenue, and financials

NovaBay Pharmaceuticals market cap is $30.6 m, and annual revenue was $6.60 m in FY 2019

$30.6 M

NBY Mkt cap, 16-Oct-2020

$4 M

NovaBay Pharmaceuticals Revenue Q2, 2020
NovaBay Pharmaceuticals Gross profit (Q2, 2020)1.9 M
NovaBay Pharmaceuticals Gross profit margin (Q2, 2020), %48.8%
NovaBay Pharmaceuticals Net income (Q2, 2020)-4.5 M
NovaBay Pharmaceuticals EBIT (Q2, 2020)-1.1 M
NovaBay Pharmaceuticals Cash, 30-Jun-20208.8 M
NovaBay Pharmaceuticals EV23.3 M

NovaBay Pharmaceuticals Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

4.5m2.8m1.3m871.0k3.6m957.0k831.0k1.1m100.0k102.0k62.0k46.0k1.0m1.2m1.7m2.7m3.4m3.7m4.1m4.1m2.9m2.8m3.1m1.5m1.8m1.6m1.9m4.0m

Cost of goods sold

22.0k16.0k43.0k130.0k18.0k42.0k148.0k253.0k269.0k479.0k566.0k588.0k698.0k521.0k251.0k479.0k332.0k341.0k403.0k401.0k581.0k2.0m

Gross profit

935.0k815.0k1.1m(30.0k)84.0k20.0k(102.0k)755.0k931.0k2.2m2.9m3.1m3.4m3.6m2.7m2.3m2.8m1.2m1.4m1.2m1.3m1.9m

Gross profit Margin, %

98%98%96%(30%)82%32%(222%)75%78%82%84%84%83%87%91%83%89%77%77%75%69%49%

Sales and marketing expense

3.1m2.9m2.7m3.7m3.4m3.3m3.4m3.0m3.2m3.5m1.5m1.5m1.6m1.4m

R&D expense

2.8m2.0m2.3m2.4m2.5m2.9m2.9m2.5m2.5m2.2m2.3m1.6m1.2m1.9m933.0k278.0k4.0k62.0k70.0k132.0k46.0k61.0k45.0k85.0k32.0k49.0k9.0k115.0k

General and administrative expense

1.3m1.1m1.5m1.4m1.2m1.6m2.0m1.5m1.7m1.7m1.9m3.4m4.4m4.4m1.7m1.3m2.2m3.1m1.7m2.3m1.6m1.4m1.3m1.6m1.2m1.3m1.3m1.5m

Operating expense total

4.1m3.1m3.8m3.7m3.7m3.5m4.2m2.9m4.1m3.8m4.2m5.0m5.6m6.3m5.7m4.4m4.9m6.9m5.2m5.7m5.1m4.4m4.6m5.2m2.8m2.9m2.8m3.0m

EBIT

440.0k(348.0k)(2.5m)(2.9m)(106.0k)(3.5m)(4.1m)(3.0m)(4.1m)(3.8m)(4.1m)(4.7m)(4.9m)(5.3m)(4.6m)(2.2m)(2.0m)(3.8m)(1.8m)(2.2m)(2.4m)(2.1m)(1.8m)(4.1m)(1.4m)(1.7m)(1.5m)(1.1m)

EBIT margin, %

10%(13%)(188%)(330%)(3%)(364%)(499%)(271%)(4078%)(3712%)(6634%)(10133%)(482%)(446%)(269%)(83%)(59%)(102%)(43%)(53%)(80%)(75%)(58%)(273%)(77%)(106%)(81%)(27%)

Interest income

724.0k

Pre tax profit

429.0k111.0k(2.5m)(2.2m)86.0k(4.0m)(4.0m)(3.8m)(3.6m)(2.9m)(4.2m)(4.6m)(4.9m)(5.2m)(5.1m)(2.7m)(3.7m)(4.0m)(1.7m)(2.4m)(2.1m)(1.6m)(1.5m)(4.2m)(2.5m)(282.0k)(1.6m)(4.5m)

Income tax expense

4.0k5.0k6.0k6.0k6.0k2.0k7.0k3.0k10.0k2.0k6.0k2.0k2.0k1.0k1.0k1.0k2.0k1.0k

Net Income

425.0k106.0k(2.5m)(2.2m)80.0k(4.0m)(4.0m)(3.8m)(3.6m)(2.9m)(4.2m)(4.6m)(4.9m)(5.2m)(5.1m)(2.7m)(3.7m)(4.0m)(1.7m)(2.4m)(2.1m)(1.6m)(1.5m)(4.2m)(2.5m)(282.0k)(1.6m)(4.5m)

NovaBay Pharmaceuticals Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

8.4m12.7m10.5m5.4m2.4m9.5m3.2m3.2m6.9m

Accounts Receivable

3.0k943.0k784.0k273.0k536.0k113.1m3.6m3.4m1.1m

Prepaid Expenses

417.0k445.0k723.0k729.0k261.0k1.7m1.8m886.0k

Inventories

23.0k231.0k521.0k1.3m2.0m504.0k280.0k492.0k

Current Assets

14.6m18.3m14.8m7.0m4.5m14.5m9.0m8.6m9.4m

PP&E

1.3m891.0k718.0k436.0k395.0k371.0k471.0k201.0k110.0k

Total Assets

16.0m19.2m15.7m7.5m5.1m15.4m10.1m9.4m11.2m

Accounts Payable

472.0k455.0k1.7m1.9m2.5m455.0k466.0k551.0k331.0k

Short-term debt

3.5m

Current Liabilities

2.8m3.2m3.6m3.3m4.6m4.3m5.0m3.8m5.7m

Long-term debt

505.0k

Total Debt

4.0m

Total Liabilities

6.6m5.2m7.1m5.7m10.2m8.3m7.5m4.4m10.2m

Common Stock

286.0k369.0k446.0k516.0k35.0k154.0k171.0k279.0k

Preferred Stock

Additional Paid-in Capital

42.4m54.0m64.4m72.9m85.4m110.6m113.5m119.8m125.7m

Retained Earnings

(90.5m)(103.7m)(111.1m)(115.0m)(125.0m)

Total Equity

9.3m14.0m8.5m1.8m(5.1m)7.1m2.6m5.0m973.0k

Financial Leverage

1.7 x1.4 x1.8 x4.1 x-1 x2.2 x3.9 x1.9 x11.5 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

8.0m12.4m6.1m4.7m7.2m8.4m6.6m6.9m10.3m7.8m7.9m5.6m7.2m3.4m1.4m3.5m9.4m7.4m5.7m6.1m8.3m6.8m5.2m2.9m3.7m9.0m5.7m8.8m

Accounts Receivable

3.6m1.8m1.0m9.0k126.0k916.0k112.0k272.0k260.0k440.0k364.0k283.0k389.0k543.0k1.5m2.1m2.3m3.6m2.2m2.2m2.0m2.6m2.4m1.5m1.5m952.0k1.4m

Prepaid Expenses

586.0k289.0k427.0k506.0k508.0k365.0k427.0k330.0k794.0k656.0k514.0k1.2m597.0k668.0k474.0k1.8m1.0m972.0k1.0m1.8m1.6m1.3m1.5m1.6m1.1m662.0k1.1m

Inventories

61.0k48.0k63.0k155.0k218.0k405.0k492.0k1.5m1.6m1.2m1.1m1.1m765.0k672.0k599.0k479.0k317.0k390.0k302.0k664.0k838.0k552.0k626.0k

Current Assets

13.4m16.8m12.8m10.9m12.5m14.5m12.0m11.5m16.4m12.9m10.4m7.6m9.6m6.2m4.6m6.6m14.4m11.5m11.0m9.9m12.8m10.8m9.5m7.1m7.5m12.5m7.9m11.9m

PP&E

1.5m1.4m1.1m1.1m1.0m819.0k761.0k687.0k658.0k488.0k478.0k408.0k375.0k359.0k370.0k366.0k282.0k421.0k462.0k492.0k435.0k351.0k271.0k193.0k177.0k128.0k97.0k84.0k

Total Assets

15.0m18.3m14.0m12.1m13.7m15.4m12.8m12.2m17.2m13.5m11.0m8.2m10.2m6.7m4.9m7.0m15.1m12.7m12.1m11.1m13.8m11.7m10.4m9.7m9.9m14.6m9.5m13.3m

Accounts Payable

448.0k320.0k439.0k901.0k1.1m539.0k611.0k1.0m487.0k520.0k918.0k2.2m1.8m2.9m1.8m860.0k387.0k798.0k908.0k356.0k301.0k329.0k564.0k462.0k356.0k503.0k602.0k1.3m

Short-term debt

1.9m3.0m1.1m

Current Liabilities

3.7m4.0m2.9m3.7m4.0m2.5m2.8m3.1m2.3m2.0m2.4m3.7m2.8m4.3m4.0m4.4m3.7m4.3m4.7m5.3m3.2m3.1m3.4m5.4m3.4m6.3m5.5m4.3m

Long-term debt

2.4m2.5m627.0k406.0k303.0k

Total Debt

2.4m2.5m2.5m3.4m1.4m

Total Liabilities

5.4m5.4m6.7m6.5m6.2m5.1m5.6m6.8m5.3m4.3m5.4m6.0m5.3m6.5m9.5m8.4m8.3m8.9m9.2m5.0m4.3m4.3m8.6m8.2m11.1m9.8m12.3m

Common Stock

235.0k283.0k288.0k289.0k297.0k369.0k374.0k387.0k507.0k508.0k511.0k611.0k736.0k746.0k92.0k149.0k153.0k153.0k154.0k171.0k171.0k171.0k171.0k207.0k252.0k282.0k346.0k

Preferred Stock

Additional Paid-in Capital

39.2m42.3m42.9m43.4m45.1m54.3m55.2m57.3m71.3m71.6m72.3m77.7m85.2m85.8m88.2m95.7m108.6m111.9m112.5m113.5m119.3m119.4m119.6m120.5m123.5m125.0m126.0m131.7m

Retained Earnings

(81.1m)(86.3m)(95.6m)(98.3m)(102.0m)(107.7m)(109.4m)(111.9m)(110.6m)(112.2m)(113.7m)(119.5m)(122.1m)(122.3m)(126.6m)(131.1m)

Total Equity

9.6m12.9m7.4m5.6m7.4m10.3m7.2m5.4m11.8m9.2m5.7m2.1m4.9m227.0k(2.5m)6.7m4.4m3.2m1.8m8.9m7.4m6.1m1.1m1.7m2.9m(349.0k)983.0k

Financial Leverage

1.6 x1.4 x1.9 x2.2 x1.8 x1.5 x1.8 x2.3 x1.5 x1.5 x1.9 x3.8 x2.1 x29.5 x-2.8 x2.3 x2.9 x3.8 x6 x1.6 x1.6 x1.7 x8.6 x5.9 x5 x-27.1 x13.5 x

NovaBay Pharmaceuticals Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.6m)(1.5m)(2.5m)(4.8m)(4.7m)(4.0m)(8.1m)(11.9m)(3.6m)(6.5m)(10.7m)(4.6m)(9.5m)(14.8m)(5.1m)(7.8m)(11.5m)(4.0m)(5.7m)(8.2m)(2.1m)(3.7m)(5.3m)(4.2m)(6.7m)(7.0m)(1.6m)(6.1m)

Depreciation and Amortization

216.0k321.0k91.0k174.0k256.0k81.0k161.0k240.0k70.0k141.0k185.0k41.0k82.0k123.0k40.0k67.0k98.0k18.0k36.0k54.0k41.0k127.0k219.0k17.0k33.0k50.0k14.0k28.0k

Accounts Receivable

3.1m1.3m(1.0m)(6.0k)(123.0k)27.0k831.0k671.0k524.0k403.0k583.0k(47.0k)(151.0k)(307.0k)(992.0k)(969.0k)(1.5m)(211.0k)(1.5m)(109.0k)1.9m2.1m1.5m954.0k1.8m1.9m113.0k(498.0k)

Inventories

(38.0k)(25.0k)(40.0k)76.0k12.0k(175.0k)29.0k(871.0k)(1.0m)144.0k193.0k261.0k108.0k200.0k273.0k160.0k89.0k(21.0k)(383.0k)(558.0k)(59.0k)(134.0k)

Accounts Payable

287.0k(167.0k)167.0k785.0k1.3m(222.0k)400.0k959.0k(1.2m)(1.4m)(1.1m)357.0k(286.0k)1.1m(1.7m)(2.1m)234.0k390.0k602.0k(161.0k)(327.0k)(56.0k)(521.0k)(1.4m)(1.6m)(175.0k)473.0k

Cash From Operating Activities

(3.3m)(2.6m)(2.7m)(3.7m)(3.4m)(3.7m)(5.9m)(8.3m)(4.4m)(8.2m)(10.9m)(4.5m)(9.9m)(14.1m)(4.9m)(7.6m)(11.4m)(2.0m)(3.6m)(3.3m)(464.0k)(2.0m)(3.6m)(3.2m)(5.0m)(6.5m)(865.0k)(1.9m)

Purchases of PP&E

(117.0k)(117.0k)(4.0k)(54.0k)(9.0k)(31.0k)(36.0k)(12.0k)(21.0k)(63.0k)(14.0k)(22.0k)(46.0k)(16.0k)(38.0k)(78.0k)(59.0k)(155.0k)(228.0k)(2.0k)(5.0k)(13.0k)(14.0k)(19.0k)(19.0k)

Cash From Investing Activities

(163.0k)(1.1m)464.0k(57.0k)937.0k(686.0k)(730.0k)184.0k(2.3m)(1.2m)1.3m23.0k15.0k(9.0k)(38.0k)(78.0k)(59.0k)(155.0k)(228.0k)(2.0k)(5.0k)(13.0k)(14.0k)(19.0k)(19.0k)

Short-term Borrowings

(71.0k)(71.0k)(71.0k)

Long-term Borrowings

(106.0k)(106.0k)(2.5m)(3.0m)(565.0k)(2.1m)

Dividends Paid

Cash From Financing Activities

(64.0k)4.6m(35.0k)(28.0k)1.3m30.0k477.0k2.3m6.6m6.6m7.0m4.7m11.7m12.0m4.0m8.7m18.6m(48.0k)(10.0k)136.0k5.6m5.6m5.6m3.0m5.5m12.4m(364.0k)3.7m

Net Change in Cash

(3.6m)896.0k(2.3m)(3.8m)(1.2m)(4.3m)(6.1m)(5.8m)(184.0k)(2.7m)(2.6m)169.0k1.8m(2.0m)1.1m7.0m(2.1m)(3.8m)(3.4m)5.1m3.6m2.0m(251.0k)485.0k5.8m(1.2m)1.8m

Interest Paid

44.0k51.0k35.0k55.0k

NovaBay Pharmaceuticals Ratios

USDQ2, 2011

Financial Leverage

1.6 x